Cancer Network

01/25/2025

A total of 6 patients experienced serious AEs, and 3 patients died after data cutoff although no deaths were determined to be related to treatment.

Cohort 5 of the ongoing phase 1/2 GOBLET study evaluated the safety of pelareorep in combination with modified FOLFIRINOX with or without atezolizumab in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.

01/25/2025

Panelists discuss how the treatment paradigm for newly diagnosed multiple myeloma has evolved from conventional chemotherapy to modern regimens incorporating novel agents.

Panelists discuss how the treatment paradigm for newly diagnosed multiple myeloma (NDMM) has evolved from conventional chemotherapy to modern regimens incorporating novel agents like proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies while highlighting persistent challenges inc...

01/25/2025

Among patients with ctDNA-negative colon cancer following surgery and before treatment with celecoxib or placebo (n = 767), the estimated 3-year DFS rate was 86.5% (95% CI, 84.0%-89.1%).

Subgroup analysis of the CALGB/SWOG 80702 trial investigated the impact of ctDNA status on DFS in stage III resected colon cancer patients treated with celecoxib or placebo.

01/25/2025

“[The] NALIRIFOX regimen in the NAPOLI 3 trial showed numerically improved OS compared to [FOLFIRINOX], including [modified FOLFIRINOX] in the real-world setting,” said Paul Cockrum, PharmD.

A 3-cohort retrospective analysis compared patients who met eligibility for the NAPOLI 3 trial with all-comers treated with FOLFIRINOX for PDAC.

01/25/2025

“Potential benefit was observed across clinical factors including grade, functional status, [use] concurrent somatostatin analogs, and prior treatment,” said Jonathan Strosberg, MD.

Patients who received cabozantinib experienced a PFS of 8.5 months vs 5.6 months with placebo, a subgroup analysis from the CABINET trial found.

01/25/2025

Among 20 evaluable patients, study treatment yielded a median PFS of 2.35 months (95% CI, 1.91-3.94) and a median OS of 6.44 months (95% CI, 3.81-not reached [NR]).

Updated phase 2 results support further investigation of surufatinib plus TAS-012 in a larger cohort of patients with pancreatic ductal adenocarcinoma.

01/25/2025

Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma.

Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 20...

01/25/2025

Combining TACE with camrelizumab and rivoceranib elicited a clinically meaningful and statistically significant PFS improvement among patients with unresectable hepatocellular carcinoma.

Additionally, data show a trend towards improved overall survival with TACE plus camrelizumab/rivoceranib in the phase 2 CARES-005 study.

01/24/2025

With a median follow-up of 37.1 months and 68% maturity, the median OS was 44.8 months (95% CI, 37.8-57.6) with fulvestrant vs 42.7 months (95% CI, 36.6-50.1) with anastrozole (HR, 0.97; 95% CI, 0.77-1.21; P = .76).

Data show a trend towards a reduced risk of death with fulvestrant vs anastrozole among patients with nonvisceral disease in the phase 3 FALCON trial.

01/24/2025

Evorpacept plus with trastuzumab, paclitaxel, and ramucirumab elicited favorable survival outcomes and responses compared with TRP alone in patients with HER2-positive gastric or GEJ cancer.

Phase 2 results show clinical responses and survival benefits in patients with confirmed HER2-positive expression in gastric/gastroesophageal cancer.

01/24/2025

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

01/24/2025

SHR-1701 in combination with chemotherapy demonstrated the ability to suppress chemotherapy-associated myelosuppression in patients with HER2-negative gastric/gastroesophageal junction adenocarcinoma.

SHR-1701 plus CAPOX chemotherapy elicited fewer chemo delays and dose reductions and improved AE data vs placebo plus CAPOX in HER2-negative gastric/GEJ cancer.

01/24/2025

How are oncologists reducing adverse effects following first-line treatment for patients with EGFR-mutated NSCLC? Discover the latest advancements in our newest article.

At the Mayo Clinic, a panel of oncology experts convened to explore evolving strategies for preventing immune-related adverse effects. They also shared valuable insights from clinical trials featuring amivantamab combined with lazertinib.

Read more: https://ow.ly/PFLn50UM3OF

01/24/2025

The median overall survival (OS) was not reached (NR; 95% CI, 25.4-not evaluable [NE]). The 3-year OS rate was 62.8% (95% CI, 41.6%-78.0%).

Results from the phase 2 FDZL-001 trial showed high OS and PFS rates when camrelizumab plus Nab-POF was used to treat patients with gastric/GEJ cancer.

01/23/2025

Data collected by central cancer registries reveal that cancer incidences in women ages 50 to 64 years have already surpassed those of men, with statistical equivalence observed in 2021 (832.5 vs. 830.6 per 100,000, respectively).

Of note, lung cancer incidence was higher among women younger than 65 compared with their male counterparts in 2021.

01/23/2025

IsaVRd has been approved in the EU as a treatment option for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Patients who received the isatuximab combination in the IMROZ trial experienced prolonged MRD-negativity, which correlated with improved PFS.

01/23/2025

Doxycycline/minocycline, clindamycin, chlorhexidine, and a ceramides-based noncomedogenic moisturizer reduced skin- and nail-related AEs in NSCLC.

Doxycycline/minocycline, clindamycin, chlorhexidine, and a ceramides-based noncomedogenic moisturizer reduced skin- and nail-related AEs in NSCLC.

01/23/2025

Everolimus plus lanreotide demonstrated a significant improvement in PFS compared with everolimus monotherapy, and an acceptable safety profile in the first-line treatment of patients with unresectable/recurrent GEP-NETs.

Everolimus plus lanreotide elicited a PFS of 29.7 months compared with 11.5 months from everolimus monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.